Indica makes you sleepy, sativa makes you alert. True?

Three reasons. First, the chemovar of a flower sold as an "indica" really can be myrcene-dominant, and myrcene is associated with relaxation. Second, the placebo effect plays a measurable role. People who expect sedation feel it more often. Third, time of day, tiredness, setting and dose all matter. None of this means the effect was imagined. It just means the indica label is not the cause.

In 1785 the botanist Jean-Baptiste Lamarck described a cannabis plant from India that differed morphologically from the European one. Smaller, broader, bushier. He called it Cannabis indica, in contrast to Cannabis sativa. The distinction was purely botanical: leaf shape, height, seed size. Back then it had nothing to do with effect.

The idea that indica is "sedating, for the evening" and sativa is "energizing, for the day" is a label that grew out of dispensary and grower culture in the late 1990s and 2000s. As a shorthand sales story it was useful, until the research caught up.

In a widely quoted interview, the cannabis researcher Ethan Russo called the distinction "biologically meaningless" as far as effect goes.¹

The study by Watts et al. 2021 in Nature Plants² is the sharpest piece of evidence. The team analyzed around 100 cannabis strains using more than 100,000 genetic markers. The result: sativa labels and indica labels cannot be reliably told apart across the genome.

The only correlation the researchers found was in a narrow stretch of the terpene synthase genes, the genes that govern the aroma profile. Sativa-labeled plants tended to carry more farnesene and bergamotene. That is a chemical signature, not an effect profile.

The takeaway: saying "this is an indica, it relaxes you" refers to a marketing label, not a genetic fact.

In PLoS ONE³, Smith et al. 2022 analyzed tens of thousands of commercial cannabis samples from six US states. The result: the sativa, indica and hybrid labels did not consistently match the measured chemical profiles. The same strain, say "Blue Dream" or "OG Kush", showed widely different cannabinoid and terpene levels depending on the producer.

In plain terms: two flowers with the same name and the same label can have completely different effects. The name on the packaging is not a reliable indicator of what is in the product.

A 2025 analysis⁴ in Cannabis and Cannabinoid Research is especially relevant for the German context. The team used GC-MS to study the terpene profiles of 140 medical cannabis flowers from the German market, exactly the pharmacy products that patients here work with.

The result: the terpene profiles of sativa, indica and hybrid strains are so heterogeneous that no statistical correlation with the assigned type can be shown. Instead, the authors propose a six-cluster chemovar model that groups products by chemical fingerprint, independent of the sativa/indica label.

For patients in Germany this means that anyone who tries an "indica" from the pharmacy in order to relax is betting on a label, not on an ingredient.

In the journal PhytoKeys⁵, McPartland & Small 2020 published a thorough revision. Their finding: indica and sativa denote botanical subspecies (Cannabis sativa subsp. sativa and Cannabis sativa subsp. indica) that differ in morphology, habit and chemovar type, but not in any fixed effect. They call the commercial use of the terms, as it is common in dispensaries and pharmacies, taxonomically wrong.

Calling it all nonsense would be too easy. Two truths remain.

First, there really are two botanical subspecies, and they differ in how they grow. Cannabis sativa subsp. indica is smaller and bushier, subsp. sativa grows taller and slimmer. For anyone cultivating cannabis, this distinction has practical value.

Second, there is a weak statistical tendency. Strains historically classified as indica more often had myrcene as their dominant terpene, while strains classified as sativa more often showed terpinolene, pinene or limonene profiles.⁶ That is a tendency with a lot of scatter, not a law. This is where the myth gets its plausibility. Terpenes like myrcene are associated with body-focused relaxation, while limonene and α-pinene are linked to clarity and activation. When an "indica" happens to be myrcene-dominant, the rule of thumb holds. By chance.

The difference from the rule of thumb is this: the felt effect comes from the terpene profile, not from the indica label. And since the labels do not reliably correlate with the profiles, inferring the effect from the label is a gamble.

The serious alternative is called the chemovar. Hazekamp and Fischedick 2012 introduced the term to cannabis research.⁷ A chemovar describes the chemical profile of a flower: how much THC, how much CBD, which terpenes dominate, and in what ratio.

Three questions help you assess a strain more than any indica/sativa label:

1. What is the THC:CBD ratio? Pure THC works differently from THC with a meaningful share of CBD. This is the single strongest modifier of the effect.

2. Which terpene dominates? Myrcene, limonene, β-caryophyllene, α-pinene, linalool. Each lead terpene brings a different profile.

3. Which secondary terpenes are worth noting? Trace terpenes below roughly 0.1 percent have barely any noticeable influence.

That is more information than "indica or sativa". The effort pays off because it connects to the actual pharmacology.

If indica and sativa drop out as decision criteria, you need a replacement. For pharmacy products in Germany:

Look at the certificate of analysis. Producers like Bedrocan, Tilray or Aurora supply terpene profiles. The number after the terpene name (for example "myrcene 0.8 %") says more than the label.

Note the profile, not the strain name. If a strain worked for you, write down which terpene was dominant, not what color the packaging was. On the next order you can then search by that profile, even if the specific strain is no longer available.

The strain name is no guarantee. "An indica last time" is no guarantee that the next "indica" will work the same way. Smith et al. 2022 shows that even strains with the same name vary widely between producers.

Should the indica/sativa distinction be thrown out entirely? No. It is botanically and morphologically correct and useful for breeders. But for predicting the effect on the end user it is unreliable, because modern products are almost all hybrids and the labels do not correlate with the ingredients.

Does this apply to CBD flowers too? Even more so. CBD flowers are also marketed as indica, sativa or hybrid. The evidence is the same: the terpene profile decides, not the label.

What is the best question to ask at the pharmacy? "Which terpene profile is dominant in this strain?" is the question with the highest information value. As a rule, certificates of analysis are on file and the pharmacy can give you the answer.